arrow
H

Ho Sup Lee

Kosin University Gospel Hospital
H指数:24
被引数:2,669

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prospective, multicentre phase II study to evaluate the clinical benefit of reduced-dose lenalidomide and dexamethasone based on frailty stratification in elderly, unfit patients with newly diagnosed multiple myeloma

前瞻性、多中心II期研究,旨在评估基于虚弱分层的新诊断多发性骨髓瘤老年、不适宜患者中减量来那度胺联合地塞米松的临床获益

2026-07-030
PRE
Serial next-generation sequencing for detecting germline predisposition in acute myeloid leukemia

串联下一代测序用于检测急性髓系白血病中的胚系易感性

2026-02-012
OAAI
Age- and sex-adjusted genomic differences between Korean and Beat AML cohorts

韩国和Beat AML队列经年龄和性别校正的基因组差异

2026-01-010
OA
Efficacy, safety, and health-related quality of life in transplant-ineligible newly diagnosed multiple myeloma patients receiving bortezomib maintenance therapy: a study of the Korean Multiple Myeloma Working Party KMMWP-174 study

疗效、安全性以及健康相关生活质量在非移植适应症的 newly diagnosed multiple myeloma 患者接受硼替佐米维持治疗中的应用:韩国骨髓瘤工作组 KMMWP-174 研究

2026-01-011
OA
A multicentre prospective phase II study of rituximab combined with bortezomib, lenalidomide and dexamethasone, followed by lenalidomide maintenance (R-VRD) in patients with Waldenström's macroglobulinaemia (KMM1803)

一项多中心前瞻性II期研究,评估利妥昔单抗联合硼替佐米、来那度胺和地塞米松,随后给予来那度胺维持治疗(R-VRD)在瓦尔登斯特罗姆巨球蛋白血症患者中的疗效(KMM1803)。

2025-11-010
PRE
A Phase II Clinical Study for Evaluating the Efficacy and Safety of Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone in Transplantation-Eligible Elderly Patients with Newly Diagnosed Multiple Myeloma (KMM2101)

一项评估达拉木单抗、来那度胺、硼替佐米和地塞米松在移植适用老年新诊断多发性骨髓瘤患者中有效性与安全性的II期临床研究(KMM2101)

BLOOD
IF23.1
2024-11-050
PRE
Serial Next-Generation Sequencing for Detection of Germline Predisposition in Acute Myeloid Leukemia

串联下一代测序在急性髓系白血病中胚系易感性的检测应用

BLOOD
IF23.1
2024-11-050
PRE
Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment

卡非佐米或伊沙佐米为基础治疗方案治疗的多发性骨髓瘤患者的预后影响:反应动力学及影响因素

BLOOD
IF23.1
2024-11-050
PRE
Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: results of the multicenter KMMWP2201 study
2024-06-061
OAAI
Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial

阿卡拉布替尼联合来那度胺和利妥昔单抗治疗复发/难治性侵袭性b细胞非霍奇金淋巴瘤的单臂II期临床试验

2024-03-303
OAAI
Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation
2023-08-222
OAAI
Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation
2023-06-262
OAAI